Procainamide hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for procainamide hydrochloride and what is the scope of patent protection?
Procainamide hydrochloride
is the generic ingredient in seven branded drugs marketed by Ani Pharms, Ascot, Ivax Sub Teva Pharms, Lannett, Lederle, Roxane, Vangard, Watson Labs, Parke Davis, Panray, Apothecon, Abraxis Pharm, Hospira, Intl Medication, Nexus, Pharmafair, Smith And Nephew, Solopak, Warner Chilcott, West-ward Pharms Int, Inwood Labs, Sandoz, Parkedale, and King Pharms, and is included in seventy NDAs. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for procainamide hydrochloride. Five suppliers are listed for this compound.
Summary for procainamide hydrochloride
| US Patents: | 0 |
| Tradenames: | 7 |
| Applicants: | 24 |
| NDAs: | 70 |
| Drug Master File Entries: | 4 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 16 |
| Patent Applications: | 1,898 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in procainamide hydrochloride? | procainamide hydrochloride excipients list |
| DailyMed Link: | procainamide hydrochloride at DailyMed |
Recent Clinical Trials for procainamide hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Abant Izzet Baysal University | N/A |
| Jeffrey Moak | Phase 4 |
| Ottawa Hospital Research Institute | Phase 4 |
Pharmacology for procainamide hydrochloride
| Drug Class | Antiarrhythmic |
Medical Subject Heading (MeSH) Categories for procainamide hydrochloride
US Patents and Regulatory Information for procainamide hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | INJECTABLE;INJECTION | 087080-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Apothecon | PRONESTYL | procainamide hydrochloride | CAPSULE;ORAL | 007335-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Watson Labs | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | CAPSULE;ORAL | 087021-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Lederle | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | CAPSULE;ORAL | 086952-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ivax Sub Teva Pharms | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | CAPSULE;ORAL | 084604-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | INJECTABLE;INJECTION | 206332-002 | Oct 13, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for procainamide hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms | PROCANBID | procainamide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020545-002 | Jan 31, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| King Pharms | PROCANBID | procainamide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020545-001 | Jan 31, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
